Vertex announces european commission approval for kalydeco® (ivacaftor) as first and only cftr modulator to treat eligible infants with cystic fibrosis as early as four months of age

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european commission has granted approval of the label extension for kalydeco® (ivacaftor) granules to include the treatment of infants with cystic fibrosis (cf) ages 4 months and older and weighing at least 5 kg who have the r117h mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g55
VRTX Ratings Summary
VRTX Quant Ranking